An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines

Biological Chemistry

Volumn 389, Issue 6, 2008, Pages 773-780

  Paliouras, Miltiadis ^a,b   Diamandis, Eleftherios P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

Author keywords

AKT activity; Androgen receptor; Androgen independent; Prostate cancer; Prostate specific antigen

Indexed keywords

ANDROGEN; EPIDERMAL GROWTH FACTOR; PROSTATE SPECIFIC ANTIGEN; PROTEIN KINASE B;

CANCER CELL; CELL LINE; CONFERENCE PAPER; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; PHOSPHORYLATION; PRIORITY JOURNAL; PROSTATE CANCER;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROGENS; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PHOSPHORYLATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 47549118308     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2008.072     Document Type: Conference Paper

References (37)

1. Bakin, A.V., Tomlinson, A.K., Bhowmick, N.A., Moses, H.L., and Arteaga, C.L. (2000). Phosphatidylinositol 3-kinase function is required for transforming growth factor β-mediated epithelial to mesenchymal transition and cell migration. J. Biol. Chem. 275, 36803-36810.
2. Bakin, R.E., Gioeli, D., Sikes, R.A., Bissonette, E.A., and Weber, M.J. (2003). Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 63, 1981-1989.
3. Balk, S.P., Ko, Y.J., and Bubley, G.J. (2003). Biology of prostate-specific antigen. J. Clin. Oncol. 21, 383-391.
4. Bonaccorsi, L., Carloni, V., Muratori, M., Formigli, L., Zecchi, S., Forti, G., and Baldi, E. (2004a). EGF receptor (EGFR) signaling promoting invasion is disrupted in androgen-sensitive prostate cancer cells by an interaction between EGFR and androgen receptor (AR). Int. J. Cancer 112, 78-86.
5. Bonaccorsi, L., Marchiani, S., Muratori, M., Carloni, V., Forti, G., and Baldi, E. (2004b). Signaling mechanisms that mediate invasion in prostate cancer cells. Ann. NY Acad. Sci. 1028, 283-288.
6. Boyer, B., Valles, A.M., and Edme, N. (2000). Induction and regulation of epithelial-mesenchymal transitions. Biochem. Pharmacol. 60, 1091-1099.
7. Ferguson, R.A., Yu, H., Kalyvas, M., Zammit, S., and Diamandis, E.P. (1996). Ultrasensitive detection of prostate-specific antigen by a time-resolved immunofluorometric assay and the Immulite immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin. Chem. 42, 675-684.
8. Gao, H., Ouyang, X., Banach-Petrosky, W.A., Gerald, W.L., Shen, M.M., and bate-Shen, C. (2006). Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer. Proc. Natl. Acad. Sci. USA 103, 14477-14482.
9. Gelmann, E.P. (1996). Androgen receptor mutations in prostate cancer. Cancer Treat. Res. 87, 285-302.
10. Gioeli, D., Ficarro, S.B., Kwiek, J.J., Aaronson, D., Hancock, M., Catling, A.D., White, F.M., Christian, R.E., Settlage, R.E., Shabanowitz, J., et al. (2002). Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J. Biol. Chem. 277, 29304-29314.
11. Grille, S.J., Bellacosa, A., Upson, J., Klein-Szanto, A.J., van Roy, F., Lee-Kwon, W., Donowitz, M., Tsichlis, P.N., and Larue, L. (2003). The protein kinase Akt induces epithelial mesenchymal transition and promotes enhanced motility and invasiveness of squamous cell carcinoma lines. Cancer Res. 63, 2172-2178.
12. Grossmann, M.E., Huang, H., and Tindall, D.J. (2001). Androgen receptor signaling in androgen-refractory prostate cancer. J. Natl. Cancer Inst. 93, 1687-1697.
13. Hakariya, T., Shida, Y., Sakai, H., Kanetake, H., and Igawa, T. (2006). EGFR signaling pathway negatively regulates PSA expression and secretion via the PI3K-Akt pathway in LNCaP prostate cancer cells. Biochem. Biophys. Res. Commun. 342, 92-100.
14. Heisler, L.E., Evangelou, A., Lew, A.M., Trachtenberg, J., Elsholtz, H.P., and Brown, T.J. (1997). Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Mol. Cell. Endocrinol. 126, 59-73.
15. Hernandez, J. and Thompson, I.M. (2004). Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer 101, 894-904.
16. Huang, Y.W., Wang, L.S., Chang, H.L., Ye, W., Shu, S., Sugimoto, Y., and Lin, Y.C. (2006). Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells. J. Steroid Biochem. Mol. Biol. 100, 24-33.
17. Kato, S., Sato, T., Watanabe, T., Takemasa, S., Masuhiro, Y., Ohtake, F., and Matsumoto, T. (2005). Function of nuclear sex hormone receptors in gene regulation. Cancer Chemother. Pharmacol. 56 (Suppl. 1), 4-9.
18. Kim, J. and Coetzee, G.A. (2004). Prostate specific antigen gene regulation by androgen receptor. J. Cell. Biochem. 93, 233-241.
19. Larue, L. and Bellacosa, A. (2005). Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 39 kinase/AKT pathways. Oncogene 24, 7443-7454.
20. Lee, J.M., Dedhar, S., Kalluri, R., and Thompson, E.W. (2006). The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J. Cell Biol. 172, 973-981.
21. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S.I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947.
22. Li, L., Ittmann, M.M., Ayala, G., Tsai, M.J., Amato, R.J., Wheeler, T.M., Miles, B.J., Kadmon, D., and Thompson, T.C. (2005). The emerging role of the PI3-K-Akt pathway in prostate cancer progression. Prostate Cancer Prostatic Dis. 8, 108-118.
23. Lin, H.K., Hu, Y.C., Yang, L., Altuwaijri, S., Chen, Y.T., Kang, H.Y., and Chang, C. (2003). Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J. Biol. Chem. 278, 50902-50907.
24. Lin, H.K., Yeh, S., Kang, H.Y., and Chang, C. (2001). Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl. Acad. Sci. USA 98, 7200-7205.
25. McCubrey, J.A., Steelman, L.S., Abrams, S.L., Lee, J.T., Chang, F., Bertrand, F.E., Navolanic, P.M., Terrian, D.M., Franklin, R.A., D'Assoro, A.B., et al. (2006). Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 46, 249-279.
26. Pienta, K.J. and Bradley, D. (2006). Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res. 12, 1665-1671.
27. Pousette, A., Grande, M., Carlstrom, K., and Stege, R. (1999). Tissue PSA is the best predicting variable for the outcome of endocrine treatment of prostatic carcinoma. Scand. J. Clin. Lab. Invest. Suppl. 229, 27-32.
28. Rajalingam, K., Schreck, R., Rapp, U.R., and Albert, S. (2007). Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 1773, 1177-1195.
29. Shand, R.L. and Gelmann, E.P. (2006). Molecular biology of prostate-cancer pathogenesis. Curr. Opin. Urol. 16, 123-131.
30. Suzuki, H., Ueda, T., Ichikawa, T., and Ito, H. (2003). Androgen receptor involvement in the progression of prostate cancer. Endocr. Relat. Cancer 10, 209-216.
31. Taplin, M.E. and Balk, S.P. (2004). Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J. Cell. Biochem. 91, 483-490.
32. Taplin, M.E., Bubley, G.J., Shuster, T.D., Frantz, M.E., Spooner, A.E., Ogata, G.K., Keer, H.N., and Balk, S.P. (1995). Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332, 1393-1398.
33. Trapman, J. and Cleutjens, K.B. (1997). Androgen-regulated gene expression in prostate cancer. Semin. Cancer Biol. 8, 29-36.
34. Van Bokhoven, A., Varella-Garcia, M., Korch, C., Johannes, W.U., Smith, E.E., Miller, H.L., Nordeen, S.K., Miller, G.J., and Lucia, M.S. (2003). Molecular characterization of human prostate carcinoma cell lines. Prostate 57, 205-225.
35. Wang, S.C. and Hung, M.C. (2001). HER2 overexpression and cancer targeting. Semin. Oncol. 28, 115-124.
36. Xin, L., Teitell, M.A., Lawson, D.A., Kwon, A., Mellinghoff, I.K., and Witte, O.N. (2006). Progression of prostate cancer by synergy of AKT with genotropic and nongenotropic actions of the androgen receptor. Proc. Natl. Acad. Sci. USA 103, 7789-7794.
37. Yang, L., Wang, L., Lin, H.K., Kan, P.Y., Xie, S., Tsai, M.Y., Wang, P.H., Chen, Y.T., and Chang, C. (2003). Interleukin-6 differentially regulates androgen receptor transactivation via PI3KAkt, STAT3, and MAPK, three distinct signal pathways in prostate cancer cells. Biochem. Biophys. Res. Commun. 305, 462-469.